Jim Bakken

Jim Bakken

| This email address is being protected from spambots. You need JavaScript enabled to view it.
jimb@uab.edu • (205) 934-3887
Chief Communications Officer, Public Relations 

As chief communications officer for the University of Alabama at Birmingham and UAB Medicine, Bakken leads teams that set and execute internal and external communications strategy. Prior to joining UAB in 2012, Bakken spent a decade working with a diverse client base at two full-service communications firms. Bakken spent eight years in Nashville at McNeely Pigott and Fox – one of the largest PR firms in the Southeast – prior to launching Peritus Public Relations in Birmingham in 2010. Bakken has served on the board of the Plank Center for Leadership in Public Relations, is accredited by the Public Relations Society of America and has been a Birmingham Business Journal Top 40 Under 40 honoree.

The UAB Political Science Club on Friday is hosting a "Meet the Candidates" debate for Alabama House of Representatives districts 52, 54 and 55. The three districts were chosen because of their proximity to the UAB campus.
Genkyotex, a developer of selective NOX enzyme inhibitors, announced today the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis.
In the first six months of the 2013-14 fiscal year, UAB supporters have exceeded the amount gifted online in the entirety of 2012-13.
Four undergraduate students have been named to the first honors class citing of their outstanding academic achievements.
The Birmingham Business Alliance is performing better than its peer cities in two-thirds of its 12 key measurements, but its chief executive said there is plenty of room for improvement.
While the source of of an individual’s allergy varies, tree pollen is a primary problem during the spring for people who suffer from allergies, according Dr. Richard Waguespack, an ear, nose and throat specialist and clinical professor at the University of Alabama at Birmingham.
“Specifically, we were able to demonstrate that established fibrosis in lungs of aged mice is partially reversed by administration of GKT137831, a new NOX inhibitor from Genkyotex,” explained Victor J. Thannickal, MD, Professor of Medicine and Pathology, Director, Division of Pulmonary, Allergy, and Critical Care, University of Alabama at Birmingham.
The University of Alabama System Board of Trustees approved two endowed positions, an endowed lectureship and three emeritus promotions.
Candidates for the State House of Representatives will attend a forum at UAB
"Failure of this trial to reach its primary efficacy endpoint has forced me (and everybody else) to rethink this issue. Much more clinical and preclinical research is needed before we can define the role of renal denervation in the management of hypertension and its complications/comorbidities.Suzanne Oparil, MD, University of Alabama at Birmingham.
Page 23 of 173